Page last updated: 2024-12-06

thiamorpholine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Thiamorpholine is a heterocyclic compound containing both sulfur and nitrogen atoms in its ring structure. It is a derivative of morpholine, where an oxygen atom is replaced by a sulfur atom. Thiamorpholine has been investigated as a potential building block for various organic molecules, including pharmaceuticals, agrochemicals, and materials. Its synthesis involves reacting 2-aminoethanethiol with 1,2-dibromoethane under appropriate conditions. The biological activity of thiamorpholine derivatives has been studied, and some compounds have exhibited promising results in areas like anti-inflammatory, anti-cancer, and anti-bacterial activities. The sulfur atom in thiamorpholine plays a crucial role in its chemical properties and biological activity, often acting as a nucleophile or coordinating center in reactions. The research on thiamorpholine focuses on exploring its synthetic versatility, investigating its biological effects, and developing new applications based on its unique properties.'

thiamorpholine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

thiomorpholine : A saturated organic heteromonocyclic parent that is an analogue of morpholine where the oxygen atom is replaced by sulfur. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID67164
CHEMBL ID2333141
CHEBI ID36392
SCHEMBL ID2273
SCHEMBL ID9487277
MeSH IDM0092770

Synonyms (47)

Synonym
1-thia-4-azacyclohexane
tetrahydro-1,4-thiazine
1,4-thiazane
parathiazan
1,4-thiazan
123-90-0
thiazolidinane
CHEBI:36392 ,
EN300-33437
thiamorpholine
thiomorpholine
inchi=1/c4h9ns/c1-3-6-4-2-5-1/h5h,1-4h
thiomorpholine, 98%
T-3790
AKOS005137922
T1007
A805163
einecs 204-660-2
unii-3a8r61g6qv
3a8r61g6qv ,
bdbm50428736
tetrahydro-2h-1,4-thiazine
FT-0631719
thiamorpholine [mi]
CHEMBL2333141 ,
AM807014
SCHEMBL2273
SCHEMBL9487277
thiomopholine
thio-morpholine
thiomorphline
1,4-thiazine, tetrahydro-
4-thiomorpholine
DTXSID80153826
mfcd00005974
CS-W007359
F2158-0924
thiomorpholine, purum, >=97.0% (gc)
SY033134
AS-17826
Q1082882
STL193989
SB12744
P10015
tetrahydro-4h-1,4-thiazine
HY-W007359
Z352252014
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
saturated organic heteromonocyclic parent
thiomorpholines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Induced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)Kd1,000.00002.32402.56362.6500AID734888
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
DNA damage responseInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
response to cytokineInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cell fate determinationInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of autophagyInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cellular homeostasisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transportInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of anoikisInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial fusionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
release of cytochrome c from mitochondriaInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein transmembrane transporter activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
protein heterodimerization activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH3 domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
channel activityInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
BH domain bindingInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
nucleoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytoplasmInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrionInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
cytosolInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
Bcl-2 family protein complexInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
mitochondrial outer membraneInduced myeloid leukemia cell differentiation protein Mcl-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID734888Binding affinity to his-tagged Mcl-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells by ITC analysis2013European journal of medicinal chemistry, Jan, Volume: 59Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (7.89)18.7374
1990's1 (2.63)18.2507
2000's7 (18.42)29.6817
2010's21 (55.26)24.3611
2020's6 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]